0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Anti-cancer Drug Exposure Evaluation Services Market Research Report 2025
Published Date: May 2025
|
Report Code: QYRE-Auto-5J15742
Home | Market Reports | Business & Industrial| Pharmaceuticals & Biotech
Global Anti cancer Drug Exposure Evaluation Services Market Research Report 2023
BUY CHAPTERS

Global Anti-cancer Drug Exposure Evaluation Services Market Research Report 2025

Code: QYRE-Auto-5J15742
Report
May 2025
Pages:75
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES

Anti-cancer Drug Exposure Evaluation Services Market

The global market for Anti-cancer Drug Exposure Evaluation Services was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
North American market for Anti-cancer Drug Exposure Evaluation Services is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Anti-cancer Drug Exposure Evaluation Services is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The global market for Anti-cancer Drug Exposure Evaluation Services in Pharmacy is estimated to increase from $ million in 2024 to $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global companies of Anti-cancer Drug Exposure Evaluation Services include IQVIA, Labcorp, PPD, ICON, Parexel, Celerion, Syneos Health, WuXi AppTec, Frontage Laboratories, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Anti-cancer Drug Exposure Evaluation Services, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Anti-cancer Drug Exposure Evaluation Services.
The Anti-cancer Drug Exposure Evaluation Services market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Anti-cancer Drug Exposure Evaluation Services market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Anti-cancer Drug Exposure Evaluation Services companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation

Scope of Anti-cancer Drug Exposure Evaluation Services Market Report

Report Metric Details
Report Name Anti-cancer Drug Exposure Evaluation Services Market
Segment by Type
Segment by Application
  • Pharmacy
  • Hospital
  • Out-Patient Chemotherapy Area
By Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company IQVIA, Labcorp, PPD, ICON, Parexel, Celerion, Syneos Health, WuXi AppTec, Frontage Laboratories
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
  • Chapter 3: Detailed analysis of Anti-cancer Drug Exposure Evaluation Services company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
  • Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 12: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the Anti-cancer Drug Exposure Evaluation Services Market report?

Ans: The main players in the Anti-cancer Drug Exposure Evaluation Services Market are IQVIA, Labcorp, PPD, ICON, Parexel, Celerion, Syneos Health, WuXi AppTec, Frontage Laboratories

What are the Application segmentation covered in the Anti-cancer Drug Exposure Evaluation Services Market report?

Ans: The Applications covered in the Anti-cancer Drug Exposure Evaluation Services Market report are Pharmacy, Hospital, Out-Patient Chemotherapy Area

What are the Type segmentation covered in the Anti-cancer Drug Exposure Evaluation Services Market report?

Ans: The Types covered in the Anti-cancer Drug Exposure Evaluation Services Market report are Targeted Cancer Drugs, Immunotherapy Drugs, Other

Recommended Reports

Cancer Diagnostics

Cancer Drug Markets

Cancer Therapeutics

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Anti-cancer Drug Exposure Evaluation Services Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Targeted Cancer Drugs
1.2.3 Immunotherapy Drugs
1.2.4 Other
1.3 Market by Application
1.3.1 Global Anti-cancer Drug Exposure Evaluation Services Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Pharmacy
1.3.3 Hospital
1.3.4 Out-Patient Chemotherapy Area
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Anti-cancer Drug Exposure Evaluation Services Market Perspective (2020-2031)
2.2 Global Anti-cancer Drug Exposure Evaluation Services Growth Trends by Region
2.2.1 Global Anti-cancer Drug Exposure Evaluation Services Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Anti-cancer Drug Exposure Evaluation Services Historic Market Size by Region (2020-2025)
2.2.3 Anti-cancer Drug Exposure Evaluation Services Forecasted Market Size by Region (2026-2031)
2.3 Anti-cancer Drug Exposure Evaluation Services Market Dynamics
2.3.1 Anti-cancer Drug Exposure Evaluation Services Industry Trends
2.3.2 Anti-cancer Drug Exposure Evaluation Services Market Drivers
2.3.3 Anti-cancer Drug Exposure Evaluation Services Market Challenges
2.3.4 Anti-cancer Drug Exposure Evaluation Services Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Anti-cancer Drug Exposure Evaluation Services Players by Revenue
3.1.1 Global Top Anti-cancer Drug Exposure Evaluation Services Players by Revenue (2020-2025)
3.1.2 Global Anti-cancer Drug Exposure Evaluation Services Revenue Market Share by Players (2020-2025)
3.2 Global Anti-cancer Drug Exposure Evaluation Services Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Anti-cancer Drug Exposure Evaluation Services Revenue
3.4 Global Anti-cancer Drug Exposure Evaluation Services Market Concentration Ratio
3.4.1 Global Anti-cancer Drug Exposure Evaluation Services Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Anti-cancer Drug Exposure Evaluation Services Revenue in 2024
3.5 Global Key Players of Anti-cancer Drug Exposure Evaluation Services Head office and Area Served
3.6 Global Key Players of Anti-cancer Drug Exposure Evaluation Services, Product and Application
3.7 Global Key Players of Anti-cancer Drug Exposure Evaluation Services, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Anti-cancer Drug Exposure Evaluation Services Breakdown Data by Type
4.1 Global Anti-cancer Drug Exposure Evaluation Services Historic Market Size by Type (2020-2025)
4.2 Global Anti-cancer Drug Exposure Evaluation Services Forecasted Market Size by Type (2026-2031)
5 Anti-cancer Drug Exposure Evaluation Services Breakdown Data by Application
5.1 Global Anti-cancer Drug Exposure Evaluation Services Historic Market Size by Application (2020-2025)
5.2 Global Anti-cancer Drug Exposure Evaluation Services Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Anti-cancer Drug Exposure Evaluation Services Market Size (2020-2031)
6.2 North America Anti-cancer Drug Exposure Evaluation Services Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Anti-cancer Drug Exposure Evaluation Services Market Size by Country (2020-2025)
6.4 North America Anti-cancer Drug Exposure Evaluation Services Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Anti-cancer Drug Exposure Evaluation Services Market Size (2020-2031)
7.2 Europe Anti-cancer Drug Exposure Evaluation Services Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Anti-cancer Drug Exposure Evaluation Services Market Size by Country (2020-2025)
7.4 Europe Anti-cancer Drug Exposure Evaluation Services Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Anti-cancer Drug Exposure Evaluation Services Market Size (2020-2031)
8.2 Asia-Pacific Anti-cancer Drug Exposure Evaluation Services Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Anti-cancer Drug Exposure Evaluation Services Market Size by Region (2020-2025)
8.4 Asia-Pacific Anti-cancer Drug Exposure Evaluation Services Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Anti-cancer Drug Exposure Evaluation Services Market Size (2020-2031)
9.2 Latin America Anti-cancer Drug Exposure Evaluation Services Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Anti-cancer Drug Exposure Evaluation Services Market Size by Country (2020-2025)
9.4 Latin America Anti-cancer Drug Exposure Evaluation Services Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Anti-cancer Drug Exposure Evaluation Services Market Size (2020-2031)
10.2 Middle East & Africa Anti-cancer Drug Exposure Evaluation Services Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Anti-cancer Drug Exposure Evaluation Services Market Size by Country (2020-2025)
10.4 Middle East & Africa Anti-cancer Drug Exposure Evaluation Services Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 IQVIA
11.1.1 IQVIA Company Details
11.1.2 IQVIA Business Overview
11.1.3 IQVIA Anti-cancer Drug Exposure Evaluation Services Introduction
11.1.4 IQVIA Revenue in Anti-cancer Drug Exposure Evaluation Services Business (2020-2025)
11.1.5 IQVIA Recent Development
11.2 Labcorp
11.2.1 Labcorp Company Details
11.2.2 Labcorp Business Overview
11.2.3 Labcorp Anti-cancer Drug Exposure Evaluation Services Introduction
11.2.4 Labcorp Revenue in Anti-cancer Drug Exposure Evaluation Services Business (2020-2025)
11.2.5 Labcorp Recent Development
11.3 PPD
11.3.1 PPD Company Details
11.3.2 PPD Business Overview
11.3.3 PPD Anti-cancer Drug Exposure Evaluation Services Introduction
11.3.4 PPD Revenue in Anti-cancer Drug Exposure Evaluation Services Business (2020-2025)
11.3.5 PPD Recent Development
11.4 ICON
11.4.1 ICON Company Details
11.4.2 ICON Business Overview
11.4.3 ICON Anti-cancer Drug Exposure Evaluation Services Introduction
11.4.4 ICON Revenue in Anti-cancer Drug Exposure Evaluation Services Business (2020-2025)
11.4.5 ICON Recent Development
11.5 Parexel
11.5.1 Parexel Company Details
11.5.2 Parexel Business Overview
11.5.3 Parexel Anti-cancer Drug Exposure Evaluation Services Introduction
11.5.4 Parexel Revenue in Anti-cancer Drug Exposure Evaluation Services Business (2020-2025)
11.5.5 Parexel Recent Development
11.6 Celerion
11.6.1 Celerion Company Details
11.6.2 Celerion Business Overview
11.6.3 Celerion Anti-cancer Drug Exposure Evaluation Services Introduction
11.6.4 Celerion Revenue in Anti-cancer Drug Exposure Evaluation Services Business (2020-2025)
11.6.5 Celerion Recent Development
11.7 Syneos Health
11.7.1 Syneos Health Company Details
11.7.2 Syneos Health Business Overview
11.7.3 Syneos Health Anti-cancer Drug Exposure Evaluation Services Introduction
11.7.4 Syneos Health Revenue in Anti-cancer Drug Exposure Evaluation Services Business (2020-2025)
11.7.5 Syneos Health Recent Development
11.8 WuXi AppTec
11.8.1 WuXi AppTec Company Details
11.8.2 WuXi AppTec Business Overview
11.8.3 WuXi AppTec Anti-cancer Drug Exposure Evaluation Services Introduction
11.8.4 WuXi AppTec Revenue in Anti-cancer Drug Exposure Evaluation Services Business (2020-2025)
11.8.5 WuXi AppTec Recent Development
11.9 Frontage Laboratories
11.9.1 Frontage Laboratories Company Details
11.9.2 Frontage Laboratories Business Overview
11.9.3 Frontage Laboratories Anti-cancer Drug Exposure Evaluation Services Introduction
11.9.4 Frontage Laboratories Revenue in Anti-cancer Drug Exposure Evaluation Services Business (2020-2025)
11.9.5 Frontage Laboratories Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
 Table 1. Global Anti-cancer Drug Exposure Evaluation Services Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
 Table 2. Key Players of Targeted Cancer Drugs
 Table 3. Key Players of Immunotherapy Drugs
 Table 4. Key Players of Other
 Table 5. Global Anti-cancer Drug Exposure Evaluation Services Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
 Table 6. Global Anti-cancer Drug Exposure Evaluation Services Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 7. Global Anti-cancer Drug Exposure Evaluation Services Market Size by Region (2020-2025) & (US$ Million)
 Table 8. Global Anti-cancer Drug Exposure Evaluation Services Market Share by Region (2020-2025)
 Table 9. Global Anti-cancer Drug Exposure Evaluation Services Forecasted Market Size by Region (2026-2031) & (US$ Million)
 Table 10. Global Anti-cancer Drug Exposure Evaluation Services Market Share by Region (2026-2031)
 Table 11. Anti-cancer Drug Exposure Evaluation Services Market Trends
 Table 12. Anti-cancer Drug Exposure Evaluation Services Market Drivers
 Table 13. Anti-cancer Drug Exposure Evaluation Services Market Challenges
 Table 14. Anti-cancer Drug Exposure Evaluation Services Market Restraints
 Table 15. Global Anti-cancer Drug Exposure Evaluation Services Revenue by Players (2020-2025) & (US$ Million)
 Table 16. Global Anti-cancer Drug Exposure Evaluation Services Market Share by Players (2020-2025)
 Table 17. Global Top Anti-cancer Drug Exposure Evaluation Services Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Anti-cancer Drug Exposure Evaluation Services as of 2024)
 Table 18. Ranking of Global Top Anti-cancer Drug Exposure Evaluation Services Companies by Revenue (US$ Million) in 2024
 Table 19. Global 5 Largest Players Market Share by Anti-cancer Drug Exposure Evaluation Services Revenue (CR5 and HHI) & (2020-2025)
 Table 20. Global Key Players of Anti-cancer Drug Exposure Evaluation Services, Headquarters and Area Served
 Table 21. Global Key Players of Anti-cancer Drug Exposure Evaluation Services, Product and Application
 Table 22. Global Key Players of Anti-cancer Drug Exposure Evaluation Services, Date of Enter into This Industry
 Table 23. Mergers & Acquisitions, Expansion Plans
 Table 24. Global Anti-cancer Drug Exposure Evaluation Services Market Size by Type (2020-2025) & (US$ Million)
 Table 25. Global Anti-cancer Drug Exposure Evaluation Services Revenue Market Share by Type (2020-2025)
 Table 26. Global Anti-cancer Drug Exposure Evaluation Services Forecasted Market Size by Type (2026-2031) & (US$ Million)
 Table 27. Global Anti-cancer Drug Exposure Evaluation Services Revenue Market Share by Type (2026-2031)
 Table 28. Global Anti-cancer Drug Exposure Evaluation Services Market Size by Application (2020-2025) & (US$ Million)
 Table 29. Global Anti-cancer Drug Exposure Evaluation Services Revenue Market Share by Application (2020-2025)
 Table 30. Global Anti-cancer Drug Exposure Evaluation Services Forecasted Market Size by Application (2026-2031) & (US$ Million)
 Table 31. Global Anti-cancer Drug Exposure Evaluation Services Revenue Market Share by Application (2026-2031)
 Table 32. North America Anti-cancer Drug Exposure Evaluation Services Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 33. North America Anti-cancer Drug Exposure Evaluation Services Market Size by Country (2020-2025) & (US$ Million)
 Table 34. North America Anti-cancer Drug Exposure Evaluation Services Market Size by Country (2026-2031) & (US$ Million)
 Table 35. Europe Anti-cancer Drug Exposure Evaluation Services Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 36. Europe Anti-cancer Drug Exposure Evaluation Services Market Size by Country (2020-2025) & (US$ Million)
 Table 37. Europe Anti-cancer Drug Exposure Evaluation Services Market Size by Country (2026-2031) & (US$ Million)
 Table 38. Asia-Pacific Anti-cancer Drug Exposure Evaluation Services Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 39. Asia-Pacific Anti-cancer Drug Exposure Evaluation Services Market Size by Region (2020-2025) & (US$ Million)
 Table 40. Asia-Pacific Anti-cancer Drug Exposure Evaluation Services Market Size by Region (2026-2031) & (US$ Million)
 Table 41. Latin America Anti-cancer Drug Exposure Evaluation Services Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 42. Latin America Anti-cancer Drug Exposure Evaluation Services Market Size by Country (2020-2025) & (US$ Million)
 Table 43. Latin America Anti-cancer Drug Exposure Evaluation Services Market Size by Country (2026-2031) & (US$ Million)
 Table 44. Middle East & Africa Anti-cancer Drug Exposure Evaluation Services Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 45. Middle East & Africa Anti-cancer Drug Exposure Evaluation Services Market Size by Country (2020-2025) & (US$ Million)
 Table 46. Middle East & Africa Anti-cancer Drug Exposure Evaluation Services Market Size by Country (2026-2031) & (US$ Million)
 Table 47. IQVIA Company Details
 Table 48. IQVIA Business Overview
 Table 49. IQVIA Anti-cancer Drug Exposure Evaluation Services Product
 Table 50. IQVIA Revenue in Anti-cancer Drug Exposure Evaluation Services Business (2020-2025) & (US$ Million)
 Table 51. IQVIA Recent Development
 Table 52. Labcorp Company Details
 Table 53. Labcorp Business Overview
 Table 54. Labcorp Anti-cancer Drug Exposure Evaluation Services Product
 Table 55. Labcorp Revenue in Anti-cancer Drug Exposure Evaluation Services Business (2020-2025) & (US$ Million)
 Table 56. Labcorp Recent Development
 Table 57. PPD Company Details
 Table 58. PPD Business Overview
 Table 59. PPD Anti-cancer Drug Exposure Evaluation Services Product
 Table 60. PPD Revenue in Anti-cancer Drug Exposure Evaluation Services Business (2020-2025) & (US$ Million)
 Table 61. PPD Recent Development
 Table 62. ICON Company Details
 Table 63. ICON Business Overview
 Table 64. ICON Anti-cancer Drug Exposure Evaluation Services Product
 Table 65. ICON Revenue in Anti-cancer Drug Exposure Evaluation Services Business (2020-2025) & (US$ Million)
 Table 66. ICON Recent Development
 Table 67. Parexel Company Details
 Table 68. Parexel Business Overview
 Table 69. Parexel Anti-cancer Drug Exposure Evaluation Services Product
 Table 70. Parexel Revenue in Anti-cancer Drug Exposure Evaluation Services Business (2020-2025) & (US$ Million)
 Table 71. Parexel Recent Development
 Table 72. Celerion Company Details
 Table 73. Celerion Business Overview
 Table 74. Celerion Anti-cancer Drug Exposure Evaluation Services Product
 Table 75. Celerion Revenue in Anti-cancer Drug Exposure Evaluation Services Business (2020-2025) & (US$ Million)
 Table 76. Celerion Recent Development
 Table 77. Syneos Health Company Details
 Table 78. Syneos Health Business Overview
 Table 79. Syneos Health Anti-cancer Drug Exposure Evaluation Services Product
 Table 80. Syneos Health Revenue in Anti-cancer Drug Exposure Evaluation Services Business (2020-2025) & (US$ Million)
 Table 81. Syneos Health Recent Development
 Table 82. WuXi AppTec Company Details
 Table 83. WuXi AppTec Business Overview
 Table 84. WuXi AppTec Anti-cancer Drug Exposure Evaluation Services Product
 Table 85. WuXi AppTec Revenue in Anti-cancer Drug Exposure Evaluation Services Business (2020-2025) & (US$ Million)
 Table 86. WuXi AppTec Recent Development
 Table 87. Frontage Laboratories Company Details
 Table 88. Frontage Laboratories Business Overview
 Table 89. Frontage Laboratories Anti-cancer Drug Exposure Evaluation Services Product
 Table 90. Frontage Laboratories Revenue in Anti-cancer Drug Exposure Evaluation Services Business (2020-2025) & (US$ Million)
 Table 91. Frontage Laboratories Recent Development
 Table 92. Research Programs/Design for This Report
 Table 93. Key Data Information from Secondary Sources
 Table 94. Key Data Information from Primary Sources
 Table 95. Authors List of This Report


List of Figures
 Figure 1. Anti-cancer Drug Exposure Evaluation Services Picture
 Figure 2. Global Anti-cancer Drug Exposure Evaluation Services Market Size Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Anti-cancer Drug Exposure Evaluation Services Market Share by Type: 2024 VS 2031
 Figure 4. Targeted Cancer Drugs Features
 Figure 5. Immunotherapy Drugs Features
 Figure 6. Other Features
 Figure 7. Global Anti-cancer Drug Exposure Evaluation Services Market Size by Application (2020-2031) & (US$ Million)
 Figure 8. Global Anti-cancer Drug Exposure Evaluation Services Market Share by Application: 2024 VS 2031
 Figure 9. Pharmacy Case Studies
 Figure 10. Hospital Case Studies
 Figure 11. Out-Patient Chemotherapy Area Case Studies
 Figure 12. Anti-cancer Drug Exposure Evaluation Services Report Years Considered
 Figure 13. Global Anti-cancer Drug Exposure Evaluation Services Market Size (US$ Million), Year-over-Year: 2020-2031
 Figure 14. Global Anti-cancer Drug Exposure Evaluation Services Market Size, (US$ Million), 2020 VS 2024 VS 2031
 Figure 15. Global Anti-cancer Drug Exposure Evaluation Services Market Share by Region: 2024 VS 2031
 Figure 16. Global Anti-cancer Drug Exposure Evaluation Services Market Share by Players in 2024
 Figure 17. Global Top Anti-cancer Drug Exposure Evaluation Services Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Anti-cancer Drug Exposure Evaluation Services as of 2024)
 Figure 18. The Top 10 and 5 Players Market Share by Anti-cancer Drug Exposure Evaluation Services Revenue in 2024
 Figure 19. North America Anti-cancer Drug Exposure Evaluation Services Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 20. North America Anti-cancer Drug Exposure Evaluation Services Market Share by Country (2020-2031)
 Figure 21. United States Anti-cancer Drug Exposure Evaluation Services Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 22. Canada Anti-cancer Drug Exposure Evaluation Services Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 23. Europe Anti-cancer Drug Exposure Evaluation Services Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 24. Europe Anti-cancer Drug Exposure Evaluation Services Market Share by Country (2020-2031)
 Figure 25. Germany Anti-cancer Drug Exposure Evaluation Services Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 26. France Anti-cancer Drug Exposure Evaluation Services Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 27. U.K. Anti-cancer Drug Exposure Evaluation Services Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 28. Italy Anti-cancer Drug Exposure Evaluation Services Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 29. Russia Anti-cancer Drug Exposure Evaluation Services Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 30. Nordic Countries Anti-cancer Drug Exposure Evaluation Services Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 31. Asia-Pacific Anti-cancer Drug Exposure Evaluation Services Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 32. Asia-Pacific Anti-cancer Drug Exposure Evaluation Services Market Share by Region (2020-2031)
 Figure 33. China Anti-cancer Drug Exposure Evaluation Services Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 34. Japan Anti-cancer Drug Exposure Evaluation Services Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 35. South Korea Anti-cancer Drug Exposure Evaluation Services Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 36. Southeast Asia Anti-cancer Drug Exposure Evaluation Services Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 37. India Anti-cancer Drug Exposure Evaluation Services Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 38. Australia Anti-cancer Drug Exposure Evaluation Services Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 39. Latin America Anti-cancer Drug Exposure Evaluation Services Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 40. Latin America Anti-cancer Drug Exposure Evaluation Services Market Share by Country (2020-2031)
 Figure 41. Mexico Anti-cancer Drug Exposure Evaluation Services Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 42. Brazil Anti-cancer Drug Exposure Evaluation Services Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 43. Middle East & Africa Anti-cancer Drug Exposure Evaluation Services Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 44. Middle East & Africa Anti-cancer Drug Exposure Evaluation Services Market Share by Country (2020-2031)
 Figure 45. Turkey Anti-cancer Drug Exposure Evaluation Services Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 46. Saudi Arabia Anti-cancer Drug Exposure Evaluation Services Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 47. UAE Anti-cancer Drug Exposure Evaluation Services Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 48. IQVIA Revenue Growth Rate in Anti-cancer Drug Exposure Evaluation Services Business (2020-2025)
 Figure 49. Labcorp Revenue Growth Rate in Anti-cancer Drug Exposure Evaluation Services Business (2020-2025)
 Figure 50. PPD Revenue Growth Rate in Anti-cancer Drug Exposure Evaluation Services Business (2020-2025)
 Figure 51. ICON Revenue Growth Rate in Anti-cancer Drug Exposure Evaluation Services Business (2020-2025)
 Figure 52. Parexel Revenue Growth Rate in Anti-cancer Drug Exposure Evaluation Services Business (2020-2025)
 Figure 53. Celerion Revenue Growth Rate in Anti-cancer Drug Exposure Evaluation Services Business (2020-2025)
 Figure 54. Syneos Health Revenue Growth Rate in Anti-cancer Drug Exposure Evaluation Services Business (2020-2025)
 Figure 55. WuXi AppTec Revenue Growth Rate in Anti-cancer Drug Exposure Evaluation Services Business (2020-2025)
 Figure 56. Frontage Laboratories Revenue Growth Rate in Anti-cancer Drug Exposure Evaluation Services Business (2020-2025)
 Figure 57. Bottom-up and Top-down Approaches for This Report
 Figure 58. Data Triangulation
 Figure 59. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)

OUR CUSTOMER

Nano Dimension